: iStockAnalyst.com Symbols Feed

Turnaround Expert: 8 Stocks Below 1999 Highs

Wed, 25 Nov 2009 17:17:49 GMT

"We all know that, despite the big run-up recently, many stocks are still below their highs of a year or two ago," observes turnaround expert George Putnam.[More...]

Where Are The Original Dividend Aristocrats Now?

Wed, 11 Nov 2009 18:56:14 GMT

The Dividend Aristocrats index measures the performance of S&P 500 index members that have followed a policy of consistently increasing dividends every year for at least 25 consecutive years.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

Pfizer (PFE) Reports; Should I Sell My Shares?

Tue, 20 Oct 2009 15:45:27 GMT

Now that I own some Pfizer stock (due to the acquisition of Wyeth), I feel obligated to at least post on Pfizer's earnings. (marketwatch) -The world's largest drug maker posted net income of $2.88 billion, or 43 cents a share, compared with $2.28 billion, or 34 cents a share, for the same quarter[More...]

Pfizer (PFE) Big Penalty

Mon, 19 Oct 2009 17:20:37 GMT

Following the recent merger of Pfizer (PFE) and Wyeth, a U.S. court imposed a huge fine on the company’s subsidiary Pharmacia & Upjohn for fraudulent marketing of its painkiller Bextra (valdecoxib). The penalty of $1.195 billion was the largest criminal fine ever imposed in the U.S. In addition, a criminal forfeiture of $105 million was enforced on the company.[More...]

Pfizer (PFE) Wastes No Time Realizing Cost Efficiencies

Fri, 16 Oct 2009 16:25:52 GMT

The largest deal among drug makers in the last year was completed today as Pfizer (PFE) officially merged with Wyeth (WYE). At the close of trading on Thursday, Wyeth was delisted from the NYSE. Pfizer has wasted no time in announcing some of its plans for what to do with its newest asset. Cutting costs will be a top priority as the company has announced closure of Wyeth operations in Pennsylvania and New Jersey.[More...]

BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI

Wed, 14 Oct 2009 16:31:04 GMT

On 10/14/09, Progenics Pharma (NASDAQ: PGNX) announced a deal with Wyeth to re-acquire all of the worldwide rights to the RELISTOR franchise after a one-year transition period. RELISTOR (subcutaneous injection) is the only drug approved to treat opioid-induced constipation (OIC) in patients with advanced illness receiving palliative care.[More...]

The Return Of The Financial Dividends

Fri, 02 Oct 2009 13:11:29 GMT

The financial crisis lead to dividend cuts amongst several prominent dividend payers such as Bank of America (BAC), US Bancorp (USB) and BB&T Corp. (BBT). Over the past few weeks however, several financial companies announced that they might reconsider their current dividend policies and start raising distributions in the near future.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

EDITORIAL: Difficult mix of business, science

Tue, 24 Nov 2009 14:50:00 GMT

Nov. 24--On many levels, Pfizer Inc.'s $67 billion merger with Wyeth Pharmaceuticals makes sense.
The acquisition broadens Pfizer's product line by inheriting Wyeth's vaccine, nutrition, generic drug and consumer product offerings.
The intent, in part, is to better position Pfizer for the blow it will receive when it loses patent protection in 2011 for its blockbuster drug Lipitor, a cholesterol-fighting medicine that will produce about $11.2 billion in sales this year.

: iStockAnalyst.com Symbols Feed

Turnaround Expert: 8 Stocks Below 1999 Highs

Where Are The Original Dividend Aristocrats Now?

Big Pharma And Biotech - Industry Outlook

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Pfizer (PFE) Reports; Should I Sell My Shares?

Pfizer (PFE) Big Penalty

Pfizer (PFE) Wastes No Time Realizing Cost Efficiencies

BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI

The Return Of The Financial Dividends

Which Pharma Pipelines Rank Best?

EDITORIAL: Difficult mix of business, science

Antitrust lawyer files suit to stop Pfizer merger

EDITORIAL: Infamous land grab goes for nothing

Commercial real estate facing worse days

Pfizer profit jumps 26 percent on cost cutting

The Business Diary

Pfizer Completes Takeover of Wyeth

Heads Up | Southwest Airlines Adds Flight Between KC and Baltimore

EDITORIAL: Don't Wait on Pfizer

Pa. Isn't Expected to Lose Jobs When Pfizer Acquires Wyeth

Pfizer Reports Third-Quarter 2009 Results

IQPC's Corporate Energy Management Summit to Feature Experts From, EMC, the EPA, and the DOE

Stock on the Move: SUWN - October 15, 2009

Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09

Cylex, Inc. Appoints Brad L. Stewart As Chief Executive Officer and Chairman of the Board

Metastorm Debuts New Customer Testimonial Videos ; Seven Successful Organizations Share Insights on Using EA, BPA, BPM Software in Season 5 of the 'Metastorm Customers Speak Out' Series

Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024

StockPreacher.com Issues Trading Outlook for Nabi Biopharmaceuticals

Wyeth Provides Regulatory Update on Prevnar 13* in the United States

Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook

Form 4 WYETH For: Oct 15 Filed by: STEIN LAWRENCE V (10K)

Form 4 WYETH For: Oct 15 Filed by: Wold Mary Katherine (10K)

Form 4 WYETH For: Oct 15 Filed by: TORELL JOHN R III (10K)

Form 4 WYETH For: Oct 15 Filed by: Redmond Cavan M. (10K)

Form 4 WYETH For: Oct 15 Filed by: POUSSOT BERNARD J (10K)

Form 4 WYETH For: Oct 15 Filed by: ROGERS GARY L (10K)

Form 4 WYETH For: Oct 15 Filed by: Portwood Charles A (10K)

Form 4 WYETH For: Oct 15 Filed by: POLAN MARY LAKE PH D (10K)

Form 4 WYETH For: Oct 15 Filed by: Peppard Denise M. (10K)

Form 4 WYETH For: Oct 15 Filed by: Norden Gregory (10K)